Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
2026. dec. 31.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
2026. dec. 15.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
2026. nov. 9.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
2026. okt. 30.· PHASE2 · RECRUITING· CTGOV
Publikáció
PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study.
2026. okt. 16.· JCO precision oncology· PUBMED
Vizsgálat
JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer
2026. szept. 30.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation.
2026. szept. 29.· PloS one· PUBMED
Publikáció
Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report.
2026. szept. 23.· Acta oncologica (Stockholm, Sweden)· PUBMED
Publikáció
Downregulation of miR203 Induces Overexpression of PIK3CA and Predicts Poor Prognosis of Gastric Cancer Patients [Retraction].
2026. szept. 18.· Drug design, development and therapy· PUBMED
Publikáció
Integrated Genomic Profiling of PTEN and TP53 in Cervical Neuroendocrine Carcinoma: Synergistic Roles With HER2/KRAS/PIK3CA and Implications for Precision Oncology.
2026. szept. 1.· Genes, chromosomes & cancer· PUBMED
Publikáció
Correction: Hypoxia and aspirin additively increase intracellular glutamine accumulation in PIK3CA-mutated colorectal cancer cells.
2026. aug. 31.· Scientific reports· PUBMED
Publikáció
Retraction of: APOA5 alleviates reactive oxygen species to promote oxaliplatin resistance in PIK3CA-mutated colorectal cancer.
2026. aug. 23.· Aging· PUBMED
Publikáció
PIK3CA in the transformation of EGFR ‑mutant lung adenocarcinoma to small cell lung cancer following acquired targeted therapy resistance.
2026. aug. 21.· Chinese medical journal· PUBMED
Vizsgálat
Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma
2026. aug. 14.· NA · RECRUITING· CTGOV
Publikáció
Somatic alterations in TP53, PIK3CA, and CCND1 reveal exposure-driven patterns in oral and oropharyngeal tumors.
2026. aug. 13.· Journal of the National Cancer Institute· PUBMED
Publikáció
Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.
2026. aug. 9.· International journal of gynecological cancer : official journal of the International Gynecological Cancer Society· PUBMED
Publikáció
Prevalence and clinical impact of PIK3CA and PTEN alterations from reflex genomic testing of newly diagnosed colorectal cancer: a population-based series.
2026. aug. 7.· Frontiers in oncology· PUBMED
Publikáció
Recurrent PIK3CA-E545K mutation promotes cervical cancer growth and invasion via AKT/mTOR signaling.
2026. aug. 7.· Molecular genetics and genomics : MGG· PUBMED
Publikáció
Case Report: Concomitant BRAF V600E and PIK3CA H1047R mutations in a micro-papillary thyroid carcinoma with extensive nodal metastasis.
2026. aug. 4.· Frontiers in oncology· PUBMED
Publikáció
Angiogenic switching in cerebral cavernous malformations driven by MAP3K3-PIK3CA synergy.
2026. aug. 3.· Brain : a journal of neurology· PUBMED
Publikáció
Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA.
2026. júl. 27.· Breast (Edinburgh, Scotland)· PUBMED
Publikáció
DHODH is a synthetic lethal target in PIK3CA-mutant colorectal cancer.
2026. júl. 24.· Cell reports· PUBMED
Vizsgálat
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
2026. júl. 23.· PHASE1 · RECRUITING· CTGOV
Publikáció
Performance Evaluation of a Colorectal Cancer-Associated MassARRAY-Based Hotspot Genotyping Assay for KRAS, NRAS, BRAF, and PIK3CA Using Solid Tumor Specimens.
2026. júl. 23.· Frontiers in bioscience (Landmark edition)· PUBMED
Publikáció
Correction: Multi-gene co-mutations of BRAF with TERT, PIK3CA, or TP53 are powerful predictors of central lymph node metastasis in papillary thyroid carcinoma.
2026. júl. 22.· Frontiers in endocrinology· PUBMED
Vizsgálat
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
2026. júl. 21.· PHASE1 · RECRUITING· CTGOV
Publikáció
Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis.
2026. júl. 20.· EBioMedicine· PUBMED
Publikáció
Growth of PIK3CA-driven cerebral cavernous malformations does not require microbiome stimulation.
2026. júl. 16.· JCI insight· PUBMED
Publikáció
Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression.
2026. júl. 14.· Cell communication and signaling : CCS· PUBMED
Publikáció
PIK3CA mutations and PI3K isoform expression define prognostic signatures in ovarian clear cell carcinoma.
2026. júl. 14.· Archives of gynecology and obstetrics· PUBMED